Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC001 in Recurrent or Progressive Gliomas
NCT06660056Phase 1Recruiting
- Sponsor
- Gongchu Biotechnology
- Start
- Oct 2024
- Primary completion
- Feb 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC001 oncolytic vaccinia virus in glioma (2 arms), sponsored by Gongchu Biotechnology. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
GC001 oncolytic vaccinia virus
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06660056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660056.